©
Image courtesy of Shutterstock
The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.
In an initial study led by NDS Head of Department Professor Freddie Hamdy in Oxford and Professor Jim Catto in Sheffield, the team will vaccinate 48 men with low or intermediate risk prostate cancer to document the safety of the new vaccine and measure how well the immune system to responds to it. If successful, then future larger-scale studies will assess the effectiveness of the vaccine.